title: [Effect of Immunovac-VP-4 and Kagocel immunotherapy on cytokine levels in patients with erythema nodosum].
abstract: Fixed erythema--a kind of clinical and histopathologic reaction, fixed drug eruption. The purpose of the study--the study of characteristics of the cytokine profile in patients with erythema and the dynamics of the basal levels of proinflammatory and antiinflammatory cytokines during immunotherapy. All 41 patients with fixed erythema at baseline and after treatment was carried out determination of levels of pro-, anti-inflammatory and regulatory cytokines in the serum by ELISA using test systems "Biosource" (Austria). In patients with fixed erythema Immunovac treatment increased serum IFN-gamma (p < 0.05), IL-1beta (p > 0.05), IL-6. While Kagocel led to an increase in IFN-gamma (p < 0.05), IL-1beta, IL-6 and reduction of TGF-beta (p < 0.05). At the same time in patients with fixed erythema basic therapy contributed to the significant increase in TGF-â and decrease in IL-10. Immunovac-VP-4 had the highest activity for the induction of IFN-gamma. Inclusion in the range of therapeutic and prophylactic measures in patients with fixed erythema immunomodulators promotes activation links innate and adaptive immunity triggers mechanisms, thus increasing the antiviral response in patients with erythema.
authors.forename: E V
authors.initials: EV
authors.lastname: Sorokina
authors.forename: N K
authors.initials: NK
authors.lastname: Akhmatova
authors.forename: V G
authors.initials: VG
authors.lastname: Khomenkov
authors.forename: É A
authors.initials: ÉA
authors.lastname: Akhmatov
mesh_terms: D056704:Adaptive Immunity / Q000187:drug effects; D000328:Adult; D000368:Aged; D000942:Antigens, Bacterial / Q000494:pharmacology / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004797:Enzyme-Linked Immunosorbent Assay; D004893:Erythema Nodosum / Q000097:blood* / Q000276:immunology / Q000628:therapy*; D005260:Female; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D007167:Immunotherapy; D007371:Interferon-gamma / Q000097:blood / Q000276:immunology; D016753:Interleukin-10 / Q000097:blood / Q000276:immunology; D053583:Interleukin-1beta / Q000097:blood / Q000276:immunology; D015850:Interleukin-6 / Q000097:blood / Q000276:immunology; D008297:Male; D008875:Middle Aged; D016212:Transforming Growth Factor beta / Q000097:blood / Q000276:immunology
chemical_list: D000942:Antigens, Bacterial; D000998:Antiviral Agents; C508609:IL10 protein, human; C508600:IL6 protein, human; D007155:Immunologic Factors; D053583:Interleukin-1beta; D015850:Interleukin-6; D016212:Transforming Growth Factor beta; D016753:Interleukin-10; D007371:Interferon-gamma